PLASMA SEX HORMONE-BINDING GLOBULIN BINDING CAPACITY IN BENIGN PROSTATIC HYPERTROPHY AND PROSTATIC CARCINOMA: COMPARISON WITH AN AGE DEPENDENT RISE IN NORMAL HUMAN MALES

1977 ◽  
Vol 84 (1) ◽  
pp. 207-214 ◽  
Author(s):  
M. Dennis ◽  
H.-J. Horst ◽  
M. Krieg ◽  
K. D. Voigt
Keyword(s):  
Prostatic Carcinoma ◽  
Binding Capacity ◽  
Benign Prostatic Hypertrophy ◽  
Sex Hormone ◽  
Prostatic Hypertrophy ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Age Dependent ◽  
The Mean ◽  
Age Range

ABSTRACT A method for the routine determination of plasma sex hormone-binding globulin (SHBG) binding capacity is introduced. In normal males an age dependent increase in SHBG binding capacity from 2.85 × 10−8 m in the age range 22–44 years to 4.66 × 10−8 m in the age range 45–64 years was found. A higher mean value of 6.41 × 10−8 m was obtained in normal females, 20–40 years old, and still higher values were found in females taking oral contraceptives. Although in male groups with benign prostatic hypertrophy or prostatic carcinoma the mean ages were somewhat higher than in the older normal group, a further age dependent increase in SHBG binding capacity in these diseases could not be demonstrated. In fact the mean values found were slightly although not significantly lower at 4.07 and 3.89 × 10−8 m, respectively. As expected, oestrogen treatment of males with prostatic carcinoma produced higher values.

QUANTIFICATION OF ANDROGEN BINDING, ANDROGEN TISSUE LEVELS, AND SEX HORMONE-BINDING GLOBULIN IN PROSTATE, MUSCLE AND PLASMA OF PATIENTS WITH BENIGN PROSTATIC HYPERTROPHY

1977 ◽  
Vol 86 (1) ◽  
pp. 200-215 ◽  
Author(s):  
M. Krieg ◽  
W. Bartsch ◽  
S. Herzer ◽  
H. Becker ◽  
K. D. Voigt
Keyword(s):  
Binding Capacity ◽  
Benign Prostatic Hypertrophy ◽  
Average Concentration ◽  
Sex Hormone ◽  
Prostatic Hypertrophy ◽  
Sex Hormone Binding Globulin ◽  
Receptor Protein ◽  
Hormone Binding ◽  
Tissue Levels

ABSTRACT The in vitro binding of 5α-dihydrotestosterone (5α-DHT) in benign prostatic hypertrophy (BPH), rectus abdominis muscle and plasma of 14 patients was characterized and quantified by agargel electrophoresis. The respective endogenous tissue and plasma levels of 5α-DHT and testosterone (T) were determined by radioimmunoassay, and the plasmatic sex hormone-binding globulin (SHBG) concentration was estimated in the 14 patients by an (NH4)2SO4 precipitation technique. Finally the in vitro conversion of 5α-DHT to the 5α-androstanediols in the BPH at 0°C after a 20–24 h incubation period was analyzed by thin-layer chromatography. The main results were as follows: (1) In 12 out of 14 BPH cytosols three charcoal resistant binding peaks were found, of which peak 1 represents SHBG, peak 2 the specific receptor protein and peak 3 a binding protein with relatively high binding capacity and low affinity for 5α-DHT. In two cases peak 2 was absent. In 11 out of 14 muscle cytosols three binding peaks are also present, resembling those of the BPH. (2) The receptor peak is reduced on average 38 % by unlabelled 5α-DHT, 23 % by cyproterone acetate (CYAC) and 29 % by oestradiol. The parallel data for the SHBG peak are: 62% by 5α-DHT, 22% by CYAC and 49% by oestradiol. (3) From displacement studies with unlabelled 5α-DHT the average concentration of receptor was calculated to be 12.3 fmol/mg cytosol protein (CP) in BPH, and 3.6 fmol/mg CP in muscle. Under identical conditions 39.9 fmol SHBG/mg CP and 24.1 fmol/mg CP were found in the BPH and muscle, respectively. The mean values are significantly different (P < 0.001). In plasma a mean value of 4.0 × 10−8 mol SHBG/1 was found. (4) In the BPH on average 4.43 ng 5α-DHT/g tissue and 0.23 ng T/g tissue are present, in muscle 0.45 ng 5α-DHT/g tissue and 0.71 ng T/g tissue, in plasma 0.47 ng 5α-DHT/ml and 3.89 ngT/ml. (5) Statistical calculations revealed (a) a significantly (P < 0.05) negative correlation between the endogenous 5α-DHT and T tissue levels and the available 5α-DHT receptor sites in BPH cytosol, (b) a positive correlation between plasmatic SHBG concentration and the available SHBG concentration in BPH cytosol. (6) Compared to the rat prostate, where 36 % of the incubated 5α-DHT was converted at 0°C within 20–24 h into the 5α-androstanediols, in the BPH conversion to 5α-androstanediols was negligible.

Time-resolved immunofluorometric assay of sex-hormone binding globulin.

1988 ◽  
Vol 34 (1) ◽  
pp. 63-66 ◽  
Author(s):  
S Niemi ◽  
O Mäentausta ◽  
N J Bolton ◽  
G L Hammond
Keyword(s):  
Binding Capacity ◽  
Reference Intervals ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Time Resolved ◽  
Interassay Coefficient ◽  
The Mean ◽  
Steroid Binding ◽  
The Eu

Abstract A time-resolved immunofluorometric assay (trlFMA) for human sex-hormone binding globulin (SHBG) is described in which antibody-coated tubes or microliter strip-wells and a europium (Eu) chelate-labeled monoclonal antibody are used. The trlFMA sensitivity is similar to that of other SHBG immunoassays, and other analytical variables compare favorably with an SHBG immunoradiometric assay (IRMA) kit and a steroid binding capacity assay: the interassay coefficient of variation (CV) is less than 8% and the intra-assay CV is less than 6% for concentrations between 6 and 200 nmol/L. The reference intervals (means +/- SD) for SHBG concentrations (nmol/L) in serum from 10 men, 10 women, and 10 pregnant women were 23 +/- 12, 65 +/- 39, and 439 +/- 122, respectively. In 14 hirsute women the mean +/- SD serum SHBG concentration (37 +/- 21 nmol/L) was significantly lower (P less than 0.01) than the mean for an age-matched, nonhirsute female comparison group. The trlFMA is technically simple, requires no centrifugation or separation reagent, and takes a counting time of only 1 s. In addition, the Eu-label is nontoxic, presents no waste-disposal problems, and has a long shelf life.

DISTRIBUTION AND CONCENTRATIONS OF ANDROGENS IN EPITHELIAL AND STROMAL COMPARTMENTS OF THE HUMAN BENIGN HYPERTROPHIC PROSTATE

1981 ◽  
Vol 90 (1) ◽  
pp. 125-131 ◽  
Author(s):  
N. J. BOLTON ◽  
RIITTA LAHTONEN ◽  
G. L. HAMMOND ◽  
R. VIHKO
Keyword(s):  
Column Chromatography ◽  
Benign Prostatic Hypertrophy ◽  
Sex Hormone ◽  
Prostatic Hypertrophy ◽  
The Other ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Androgen Metabolism ◽  
Cell Basis ◽  
Important Site

Prostate tissues removed from patients with benign prostatic hypertrophy were separated into epithelial and stromal components and the concentrations of testosterone, 5α-dihydrotestosterone, 5α-androstane-3α,17β-diol, 4-androstene-3,17-dione, 5α-androstanedione stanedione and androsterone in these two fractions were determined by radioimmunoassays after the purification of solvent steroid extracts by Lipidex-5000 column chromatography. On a 'per cell' basis (i.e. relative to DNA), testosterone was equally distributed between the two components, while the other androgens measured were more abundant in the stroma. The observation that 5α-reduced androgens (especially 5α-dihydrotestosterone) were more concentrated in the stroma, and that significant correlations between concentrations of metabolically related androgens were more common in the stroma than in the epithelium, indicate that the stroma is an important site of androgen metabolism in benign prostatic hypertrophic tissues. The present data also support the suggestion that 5α-dihydrotestosterone produced in the prostatic stroma may be transferred to the epithelium by way of sex hormone binding globulin in the extracellular spaces of the prostate.

SEX HORMONE BINDING GLOBULIN BINDING CAPACITY, TESTOSTERONE, 5α-DIHYDROTESTOSTERONE, OESTRADIOL AND PROLACTIN IN PLASMA OF PATIENTS WITH PROSTATIC CARCINOMA UNDER VARIOUS TYPES OF HORMONAL TREATMENT

1977 ◽  
Vol 85 (3) ◽  
pp. 650-664 ◽  
Author(s):  
W. Bartsch ◽  
H.-J. Horst ◽  
H. Becker ◽  
G. Nehse
Keyword(s):  
Cyproterone Acetate ◽  
Prostatic Carcinoma ◽  
Binding Capacity ◽  
Specific Binding ◽  
Hormonal Treatment ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Control Group ◽  
Blood Levels ◽  
Hormone Binding

ABSTRACT Sex hormone binding globulin (SHBG) binding capacity, the concentrations of testosterone (T), of 5α-dihydrotestosterone (DHT), of oestradiol-17β (Oe2), of oestrone (Oe1), of prolactin (hPr) and the percentual specific binding of T to SHBG (% TB) were measured in plasma of patients suffering from prostatic carcinoma and of a control group of similar age. No significant differences in any of the investigated parameters were found between the control group and the carcinoma patients before treatment although 15 % of the latter showed distinctly elevated hPr values. Treatment of carcinoma patients with 1) Antiandrogen (cyproterone acetate, Androcur®) resulted in a significant decrease of T, Oe2 and SHBG. The DHT/T-ratio increased. n = 5. 2) Orchidectomy caused an even more pronounced fall in T, DHT, Oe1 and Oe2 blood levels. SHBG was not altered. DHT/T-ratio increased. n = 32. 3) Cyproterone acetate after orchidectomy led to elevated hPr values. n = 5. 4) Oestrogen (diethylstilboestrol-diphosphate, Honvan®) after orchidectomy increased SHBG and hPr. n = 6. 5) Corticosteroid (Prednisone, Decortin®) after orchidectomy decreased T and SHBG below the levels found after orchidectomy alone, n = 5. 6) Diureticum (Mefruside, Baycaron®) (n = 5) or 7) a placebo (n = 7) did not alter any of the parameters measured. 8) Treatment with HCG (Primogonyl®) of patients suffering from oligozoospermia resulted in a significant increase of T, DHT and Oe2. SHBG was not altered. DHT/T-ratio decreased, n = 7.

scholarly journals Plasma sex hormone binding globulin in patients with prostatic carcinoma

Cancer ◽  
1990 ◽  
Vol 66 (2) ◽  
pp. 354-357 ◽  
Author(s):  
Marco Grasso ◽  
Arturo Buonaguidi ◽  
Roberto Mondina ◽  
Giovanni Borsellino ◽  
Caterina Lania ◽  
...  
Keyword(s):  
Prostatic Carcinoma ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding
Sign in / Sign up

Export Citation Format

Share Document